A Phase 2 Study of Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma
Latest Information Update: 24 Sep 2024
At a glance
- Drugs Cemiplimab (Primary) ; Fianlimab (Primary) ; Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 24 Sep 2024 New trial record